BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16113598)

  • 1. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
    Leppert JT; Lam JS; Belldegrun AS
    J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal cell carcinoma and interleukin-2: what are the endpoints?
    Figlin RA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
    [No Abstract]   [Full Text] [Related]  

  • 3. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal cell cancer: is immunotherapy dead?
    Wagstaff J
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer.
    Citterio G; Di Lucca G; Scaglietti U; Gilberti S; Baldini M; Rugarli C
    Acta Oncol; 1997; 36(2):228. PubMed ID: 9140444
    [No Abstract]   [Full Text] [Related]  

  • 7. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
    NĂ©grier S
    J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
    [No Abstract]   [Full Text] [Related]  

  • 8. Eosinophilia induced by interleukin-2 cancer immunotherapy may be associated with enhanced production of total IgE.
    Vecchi L; Lissoni P
    Int J Biol Markers; 1995; 10(1):59-60. PubMed ID: 7629429
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
    Taneja SS; Pierce W; Figlin R; Belldegrun A
    Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
    [No Abstract]   [Full Text] [Related]  

  • 12. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.
    Upton MP; Parker RA; Youmans A; McDermott DF; Atkins MB
    J Immunother; 2005; 28(5):488-95. PubMed ID: 16113605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy of renal cell carcinoma.
    Haas GP; Hillman GG; Redman BG; Pontes JE
    CA Cancer J Clin; 1993; 43(3):177-87. PubMed ID: 8490757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcomatoid renal cell carcinoma.
    Akhtar K; Shamshad A; Sufian Z; Tariq M
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):120-2. PubMed ID: 21196626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.